Core Insights - BiomX Inc. has entered into a securities purchase agreement for a registered direct offering and private placement, expecting gross proceeds of approximately 0.9306 per share and a concurrent private placement for 2,305,871 unregistered pre-funded warrants at the same price [3][5] - The offerings were led by Deerfield Management Company with participation from the Cystic Fibrosis Foundation and other investors, expected to close around February 27, 2025 [1][2] Clinical Development - BiomX is advancing BX004, a fixed phage cocktail for treating cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa, with topline results from the Phase 2b study anticipated in Q1 2026 [1][9] - The Phase 2b trial will enroll approximately 60 patients and is designed to monitor safety, tolerability, and clinical outcomes [9] Regulatory Status - BX004 has received Fast Track designation and Orphan Drug Designation from the FDA, with plans to present real-world evidence analysis to the FDA and European Committee for Medicinal Products for Human Use later this year [2][9] Additional Product Development - BiomX is also developing BX211, a personalized phage treatment for diabetic foot osteomyelitis, with topline results expected in Q1 2025 and Q1 2026 for different study readouts [10][11] Company Overview - BiomX is focused on developing natural and engineered phage therapies targeting harmful bacteria for chronic diseases, utilizing its BOLT platform to customize phage compositions [12]
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million